Regeneron Extends Ebola Treatment Supply Deal to 2031 as Africa's Widest Outbreak Reaches Nearly 10,000 Cases

WASHINGTON / NAIROBI — Regeneron Pharmaceuticals said on Monday, 26 October 2026, that it had extended its agreement with a United States health authority to supply additional doses of its Ebola treatment through 2031 for about $270 million, as Africa's current Ebola outbreak — the widest geographic spread of any Ebola outbreak on the continent to date — approached 10,000 cases in the Democratic Republic of Congo and spread to three other countries.

Note: This article is general news information only and is not medical advice. Anyone concerned about Ebola exposure should follow the guidance of their national health authority and the World Health Organization.

Illustration: Scientists in protective laboratory gear working on a medical treatment, representing research into Ebola therapies.

What Happened

According to Reuters, Regeneron's new agreement with the US Biomedical Advanced Research and Development Authority (BARDA) expands a contract first signed in 2020. Under it, the company will supply doses of its drug Inmazeb through 2031 for about $270 million. The US Food and Drug Administration approved Inmazeb in 2020 for infection caused by Zaire ebolavirus, the species behind several earlier outbreaks.

The current outbreak is different, and that difference is central to the story. It is caused by the Bundibugyo strain of Ebola, for which there is no approved specific antiviral treatment or licensed vaccine, Reuters reported. Regeneron said it is testing an experimental therapy, maftivimab, as a potential treatment for the Bundibugyo virus — but that therapy is not an approved treatment, and its effectiveness against this strain has not been established.

The outbreak was first reported in the Democratic Republic of Congo in May 2026 and has since spread to four countries across East, Central and West Africa, according to Reuters — the widest geographic spread of any Ebola outbreak on the continent. Congo's public health institute reported on Friday, 23 October 2026, a total of 9,964 confirmed cases with a fatality rate of around 48.6 percent since the outbreak was declared, Reuters reported on 26 October. Other Reuters reporting the same day put the toll at nearly 10,000 infections and more than 4,800 deaths in Congo.

Alongside the supply deal, there was a milestone in containment. Kenya said on Monday, 26 October, that it had released from quarantine the first group of people who had contact with its index patient — 20 people who completed 21 days of monitoring without developing symptoms and are in good health, according to Patrick Amoth, director-general in Kenya's health ministry. Kenya has reported nine Ebola cases so far, two of whom have died, while seven remaining patients are stable and receiving treatment. A further 98 people still in quarantine will be released in four waves beginning on 3 November, Amoth said.

Illustration: Health workers welcoming people leaving a quarantine facility, representing Kenya's release of its first Ebola contacts.

Background

Ebola is a severe viral disease that spreads through close contact with the bodily fluids of a person with symptoms, according to the World Health Organization. It can cause fever, vomiting and diarrhoea and, in severe cases, internal and external bleeding. There is no single cure: care is supportive, and outcomes depend heavily on early detection, isolation, and treatment of symptoms.

The Bundibugyo species was first identified in Uganda in 2007 and is distinct from the Zaire species that caused the devastating West Africa outbreak of 2014–2016 and the large eastern Congo outbreak of 2018–2020. Because existing approved treatments and vaccines were developed against Zaire ebolavirus, they cannot simply be assumed to work against Bundibugyo — which is why the current outbreak has required new vaccine trials and experimental therapies, and why the Regeneron supply deal, while significant, does not by itself solve the treatment gap for this strain.

The outbreak's spread across borders has tested regional coordination. After Congo, cases appeared in Kenya, Uganda and Nigeria. Kenya's first case died in a hospital in Nairobi on 5 October 2026, after which eight others fell ill while in quarantine, according to Kenya's health ministry. Nigeria reported its first Ebola case in more than a decade in October 2026, and genomic analysis cited by Nigerian authorities suggested it was closely related to Kenya's index case, with both patients having flown out of Uganda's Entebbe airport on the same day in early October.

That cross-border picture prompted the Africa Centres for Disease Control and Prevention (Africa CDC) to act. According to Reuters on 26 October, Ebola scientists will probe the origin of the Nigeria case, with a team led by Jean-Jacques Muyembe — the Congolese expert who co-discovered Ebola — examining sequencing data to work out where the Kenyan patient was infected. Africa CDC director-general Jean Kaseya said all countries involved were now willing to collaborate, after what he described as tension the previous week over conflicting accounts of the Nigeria patient's movements.

Why It Matters

The supply deal matters because preparedness is measured in years, not weeks. A commitment to supply Inmazeb through 2031, worth about $270 million, gives the United States a stockpile for future Zaire-strain outbreaks and keeps a production line running — even though it does not answer the Bundibugyo treatment question. For health agencies, that distinction is important: the deal strengthens readiness for one kind of Ebola while research into Bundibugyo therapies continues in parallel.

Kenya's quarantine milestone matters as a proof that containment can work. Twenty people completing 21 days of monitoring without illness, and 98 more due for release in waves from 3 November, show a contact-tracing system functioning under pressure. Amoth called the release "a milestone worth celebrating" while warning: "We cannot afford to drop our vigilance." That balance — acknowledging progress without declaring victory — is the message health officials have repeated throughout the outbreak.

The human cost of the response also came into sharp focus on 26 October. Reuters reported that youths killed a longtime nurse treating Ebola patients in the town of Bafwasende in Congo's Tshopo province on Friday, 23 October, and that other health workers were sheltering under police guard, too afraid to go home. Health officials linked the attack to misinformation, a recurring threat in eastern Congo where health workers have previously been attacked after being accused of spreading disease. Trust, in this outbreak, is as much a medical tool as any drug: without it, patients avoid care, contacts hide, and the virus spreads further.

Finally, the outbreak matters beyond the four affected countries because of what it reveals about global readiness. A Bundibugyo outbreak with no approved treatment or vaccine, spreading across four countries in five months, is a test of whether the surveillance, laboratory, and vaccine-trial systems built after earlier epidemics can move fast enough. The Africa CDC origin investigation, the Kenyan contact-tracing results, and the experimental-therapy research will all feed into that assessment.

Illustration: Community health workers in protective gear visiting a village clinic, representing frontline Ebola response work.

What Happens Next

In the coming days, Kenya's staged quarantine releases will be the most visible test of containment. Four waves of releases beginning on 3 November will return 98 people to their communities, and health officials have urged families to welcome them home — a deliberate message against stigma, which can drive contacts underground and undermine tracing.

The Africa CDC investigation into the Nigeria case origin is also expected to continue, with sequencing data examined to establish where the Kenyan index patient was infected. Its findings could clarify transmission chains between Uganda, Kenya, and Nigeria, and inform border-screening measures that have already come under scrutiny after the virus crossed from Congo.

On the treatment front, attention will turn to Regeneron's experimental maftivimab and to vaccine trials under way in Congo. Results from those efforts will take time, and none should be expected to change the course of the current outbreak quickly. What the $270 million supply deal does change, in the meantime, is the longer-term stockpile picture for Zaire-strain Ebola — and the signal it sends that governments are willing to pay to keep treatment capacity ready between outbreaks.

For Congo, where nearly 10,000 cases have been recorded, the priority remains the immediate response: safe burials, contact tracing, community engagement, and protection for health workers. The killing of the nurse in Bafwasende is a reminder that the response depends on people willing to do dangerous work in their own communities — and that protecting them, and countering the misinformation that puts them at risk, is part of stopping the virus.

Sponsored: explore today's featured sponsored offers

FAQ

What did Regeneron announce on 26 October 2026?

Regeneron said it had extended its agreement with the US Biomedical Advanced Research and Development Authority to supply additional doses of its Ebola treatment Inmazeb through 2031 for about $270 million, expanding a contract first signed in 2020, according to Reuters.

Does Inmazeb treat the current Ebola outbreak?

Not directly. Inmazeb was approved in 2020 for Zaire ebolavirus, while the current outbreak is caused by the Bundibugyo strain, for which there is no approved specific antiviral treatment or licensed vaccine. Regeneron is testing an experimental therapy, maftivimab, against Bundibugyo.

How large is the current Ebola outbreak?

Congo's public health institute reported 9,964 confirmed cases with a fatality rate of around 48.6 percent as of 23 October 2026, according to Reuters. The outbreak has spread from Congo to Kenya, Uganda, and Nigeria — four countries in total.

What progress has Kenya reported?

Kenya released its first 20 Ebola contacts from quarantine on 26 October after 21 days without symptoms. It has reported nine cases and two deaths, with seven patients stable, and 98 more contacts due for release in four waves from 3 November.

Why are health workers at risk during the outbreak?

Reuters reported that a nurse treating Ebola patients in Bafwasende, Congo, was killed on 23 October 2026, with other health workers sheltering under police guard. Officials linked such attacks to misinformation, which undermines trust and makes contact tracing and care harder.

Sources

• Reuters, "Regeneron extends US agreement for additional supply of Ebola treatment," 26 October 2026.
• Reuters, "Kenya releases first Ebola contacts from quarantine, milestone in containment efforts," 26 October 2026.
• Reuters, "Ebola scientists to probe Nigeria case origin, Africa CDC says," 26 October 2026.
• Reuters, "Protesters kill longtime nurse treating Ebola patients in Congo," 26 October 2026.
• World Health Organization, Ebola virus disease fact sheet — transmission through close contact with bodily fluids of a symptomatic person; symptoms including fever, vomiting, diarrhoea and bleeding.